2016-11-15T10:48:14-06:00 2015-12-31 KPMG LLP 60 South Street Boston MA 02111 990 2015-01-01 010211513 THE JACKSON LABORATORY % S CATHERINE LONGLEY JACK 2072886000 600 MAIN STREET BAR HARBOR ME 04609 S CATHERINE LONGLEY VP & CFO 2072886000 2016-11-11 true TARA D'AGOSTINO P01245482 6179881000 2016-11-10 2015 2017-02-10 21:41:12Z EDISON LIU 600 MAIN STREET BAR HARBOR ME 04609 304550988 false X WWW.JAX.ORG X 1929 ME WE DISCOVER PRECISE GENOMIC SOLUTIONS FOR DISEASE AND EMPOWER THE GLOBAL BIOMEDICAL COMMUNITY IN THE SHARED QUEST TO IMPROVE HUMAN HEALTH. 24 22 2080 30 -142311 -163061 91256682 89944366 181040415 210424017 12579453 2136894 6712934 1813476 291589484 304318753 2526000 1113816 0 0 129338203 150912017 241427 175252 3545129 118463524 129308727 250569154 281509812 41020330 22808941 736361322 754989281 243375369 168362562 492985953 586626719 X WE DISCOVER PRECISE GENOMIC SOLUTIONS FOR DISEASE AND EMPOWER THE GLOBAL BIOMEDICAL COMMUNITY IN THE SHARED QUEST TO IMPROVE HUMAN HEALTH. false false 123214222 86000 209835902 DEVELOP AND PROVIDE GENETIC RESOURCES - PLEASE SEE SCHEDULE O FOR DETAIL. 106610638 270280 181590 BIOMEDICAL RESEARCH - PLEASE SEE SCHEDULE O FOR DETAIL 6253893 757536 406525 EDUCATION AND TRAINING - PLEASE SEE SCHEDULE O FOR DETAIL 445965 236078753 true true false true false false false false false true true false false false true true true false false true true false false true true false false true true true true false false false false false false false false true true true false false false false false false false false true 204 0 true 2080 true true true false false false false true true false false false false X 24 22 true false false false false false false true true false false true true true true true true true true false CA CT FL ME MA NY X X X S CATHERINE LONGLEY 2072886108 600 MAIN STREET BAR HARBOR ME 04609 X EDISON T LIU MD PRESIDENT & CEO 40.0 0.0 X X 1025277 0 127798 CHARLES E HEWETT PHD EXECUTIVE VICE PRESIDENT & COO 40.0 0.0 X X 2019342 0 169955 JAMES J GALLOGLY TREASURER 1.0 0.0 X X 0 0 0 PETER F GERRITY SECRETARY 1.0 0.0 X X 0 0 0 WESLIE R JANEWAY VICE CHAIR OF THE BOARD 1.0 0.0 X X 0 0 0 DAVID J ROUX CHAIR OF THE BOARD 1.0 0.0 X X 0 0 0 THOMAS C BARRY TRUSTEE 1.0 0.0 X 0 0 0 DAVID R CABOT TRUSTEE 1.0 0.0 X 0 0 0 KATHLEEN A CORBET TRUSTEE 1.0 0.0 X 0 0 0 LOUIS J D'AMBROSIO TRUSTEE 1.0 0.0 X 0 0 0 TIMOTHY D DATTELS TRUSTEE 1.0 0.0 X 0 0 0 DAVID D ELLIMAN TRUSTEE 1.0 0.0 X 0 0 0 ANTHONY B EVNIN PHD TRUSTEE 1.0 0.0 X 0 0 0 RICHARD S GURIN TRUSTEE 1.0 0.0 X 0 0 0 LEO A HOLT TRUSTEE 1.0 0.0 X 0 0 0 RICHARD S LANNAMANN TRUSTEE 1.0 0.0 X 0 0 0 SAM R LITTLE TRUSTEE 1.0 0.0 X 0 0 0 NEAL B MILCH JD TRUSTEE 1.0 0.0 X 0 0 0 DENNIS PAUSTENBACH PHD TRUSTEE 1.0 0.0 X 0 0 0 CHARLES M RICE PHD TRUSTEE 1.0 0.0 X 0 0 0 JANET ROSSANT PHD TRUSTEE 1.0 0.0 X 0 0 0 EDWARD RUBIN MD PHD TRUSTEE 1.0 0.0 X 0 0 0 JOAN A STEITZ PHD TRUSTEE 1.0 0.0 X 0 0 0 BRIAN F WRUBLE TRUSTEE 1.0 0.0 X 0 0 0 LINDA A JENSEN CHIEF FINANCIAL OFFICER 40.0 0.0 X 375015 0 45380 ROBERT E BRAUN PHD VICE PRESIDENT RESEARCH 40.0 0.0 X 380054 0 28902 CHARLES LEE MD SCIENTIFIC DIRECTOR, JAX GM 40.0 0.0 X 348739 0 55824 AUROBINDO NAIR GENERAL MANAGER, JMCRS 40.0 0.0 X 523799 0 94130 KATHY L VANDEGRIFT ASSOCIATE GM FINANCE & OP 40.0 0.0 X 337495 0 48096 MIKE E HYDE VP EXTERNAL AFFAIRS & STRATE 40.0 0.0 X 339601 0 53340 JACQUES F BANCHEREAU PHD PROFESSOR 40.0 0.0 X 388142 0 37034 KRISTEN B ROZANSKY VICE PRESIDENT, DEV & COMMUN 40.0 0.0 X 369342 0 51188 BRIAN R LESLIE GENERAL COUNSEL 40.0 0.0 X 441578 0 45215 6548384 0 756862 211 false true false COLUMBUS IT PARTNER USA INC 1010 WASHINGTON BLVD STAMFORD CT 06901 IT CONSULTING 1075145 STARLIMS CORPORATION 4000 HOLLYWOOD BLVD SUITE 313-S HOLLYWOOD FL 33021 IT CONSULTING 928139 NAVIGATION ARTS LLC 7901 JONES BRANCH DRIVE STE 400 MCLEAN VA 22102 PRODUCT DEV. CONSULT 621192 OPTIV SECURITY INC 1125 17TH STREET SUITE 1700 DENVER CO 80202 IT CYBER SECURITY 554441 HDR ARCHITECTURE INC 8404 INDIAN HILLS DRIVE OMAHA NE 68114 ARCHITECT 436332 24 81130 75673815 14189421 3706571 89944366 GENETIC RESOURCES 541700 209835902 209835902 TRAINING & EDUCATION 541700 406525 406525 RESEARCH 541700 181590 181590 210424017 7221502 -56583 7278085 0 1682549 1682549 0 0 0 -803439 -4281169 -803439 -4281169 -5084608 -5084608 2925 81130 232235 -229310 -229310 0 0 0 0 OTHER REVENUE 900099 445965 445965 DEBT FINANCED RENTAL INCOME 531390 -85728 -85728 360237 304318753 210869982 -142311 3646716 129350 129350 984466 984466 0 0 5194216 1139614 4054602 0 110216741 89648074 19129584 1439083 8485929 7124070 1245876 115983 18939474 12730307 5984951 224216 8075657 6568576 1401638 105443 0 825129 31234 793830 65 372590 25000 347590 100751 100751 175252 175252 328453 328453 13247479 11634507 1533052 79920 915367 846945 68416 6 2204508 1512991 526445 165072 7095950 5631383 1368468 96099 33118 33118 14094009 12992152 1014978 86879 6090813 4574920 1184129 331764 0 297080 243314 51836 1930 5308427 5112557 148204 47666 0 33654197 31412382 1888199 353616 1618622 1514906 90712 13004 SUPPLIES 41516287 40701712 527256 287319 OTHER SERVICES 1882687 1652754 222745 7188 EQUIPMENT RENTAL 175952 139029 23269 13654 AP DISC, SETTLEMENTS, OTHER -452692 -304608 -149054 970 281509812 236078753 41885930 3545129 25000 0 152005357 176208238 10011476 10960430 25606040 28085464 0 0 0 0 0 0 3065793 3570577 5133276 5563846 657395235 266322226 397890353 391073009 111467212 116692811 15142592 16006283 0 0 0 0 16014223 6828623 736361322 754989281 48317692 41018259 0 0 9725794 7158622 104647760 100799778 0 0 0 0 67540155 7270000 0 0 13143968 12115903 243375369 168362562 X 439085978 528062615 38570318 40168128 15329657 18395976 492985953 586626719 736361322 754989281 X 22808941 -5949671 76781496 X false true X true true true X 41644804 67271113 74310661 91256682 89944366 364427626 0 0 41644804 67271113 74310661 91256682 89944366 364427626 34266731 330160895 2311932 2888204 7196139 10415818 8960634 31772727 33525 3588 37113 220423 225566 255201 164499 448890 1314579 397552045 803535684 0.83049 0.87630 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false true true true true false true 266410 false false 266410 false LOBBYING ACTIVITY BY NON-ELECTING 501(C)(3) ORGANIZATION PART II-B, LINE 1G THE TOTAL LOBBYING EXPENSE FOR THE YEAR ENDED DECEMBER 31, 2015 WAS $165,659, WHICH WAS AN ALLOCATION OF EMPLOYEE COMPENSATION FOR LOBBYING ACTIVITIES AND $100,751 FOR VENDOR PAYMENTS. 126609811 7348710 -728319 33750 498352 132698100 108965719 11841924 5890303 88135 126609811 90755276 6074191 13007247 870995 108965719 80841065 1280959 9091700 458448 90755276 87452850 74725 -5827854 858656 80841065 0.63440 0.12020 0.24540 false false 10468193 10468193 501559609 173847822 327711787 131174914 92474404 38700510 14192519 14192519 391073009 0 RETIREMENT PLAN OBLIGATIONS 5662348 INTEREST RATE SWAP 6453555 12115903 X 375183985 -5949671 76781495 70831824 304352161 393814 -427222 -33408 304318753 281543220 427222 427222 281115998 393814 393814 281509812 ENDOWMENT FUNDS PART V, LINE 4 THE INVESTMENT AND SPENDING POLICIES FOR THE ENDOWMENT ASSETS HAVE BEEN ESTABLISHED TO PROVIDE A PREDICTABLE STREAM OF FUNDING FOR THE PROGRAMS SUPPORTED BY ENDOWMENT INCOME, WHILE SEEKING TO MAINTAIN THE PURCHASING POWER OF THE ENDOWMENT ASSETS. IN ADDITION, WHEN CONSIDERING THE AMOUNT OF INCOME TO APPROPRIATE FROM BOARD-DESIGNATED ASSETS, THE TRUSTEES CONSIDER THE NEED TO MAINTAIN UNRESTRICTED ASSETS TO MEET LIQUIDITY COVENANTS RELATED TO OUTSTANDING BONDS. ACCORDINGLY, THE BOARD OF TRUSTEES HAS SET THE INVESTMENT ALLOCATION TO ACHIEVE A NOMINAL RATE OF RETURN THAT WILL AT LEAST COVER INFLATION AND THE SPEND RATE WITH A PRUDENT LEVEL OF RISK. THE INVESTMENT ALLOCATION FOR THE BOARD-DESIGNATED PORTION OF THE ENDOWMENT IS SET TO ACHIEVE GREATER STABILITY IN THE VALUE OF INVESTMENTS. THE BOARD ALLOCATED 4% OF THE THREE YEAR AVERAGE VALUE OF DONOR-DESIGNATED ENDOWMENT BALANCES TO SUPPORT THE DESIGNATED PROGRAMS. ALL EARNINGS ON DONOR ENDOWMENTS ESTABLISHED TO PROVIDE GENERAL SUPPORT FOR THE LABORATORY AS APPROVED BY THE BOARD OF TRUSTEES WERE RETAINED IN THE ENDOWMENT. THE BOARD OF TRUSTEES WISHES TO INCREASE THE AMOUNT OF ENDOWMENT SUPPORT AVAILABLE IN THE FUTURE. LIABILITY FOR UNCERTAIN TAX POSITIONS UNDER FIN 48 (ASC 740) PART X, LINE 2 THE LABORATORY IS A NOT-FOR-PROFIT ORGANIZATION AS DESCRIBED IN SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE (THE CODE), AS AMENDED, AND IS GENERALLY EXEMPT FROM INCOME TAXES PURSUANT TO THE CODE. IN ACCORDANCE WITH GAAP, THE LABORATORY ASSESSES WHETHER THERE ARE UNCERTAIN TAX POSITIONS AND DETERMINED THERE WERE NO UNCERTAIN TAX POSITIONS THAT WOULD HAVE A MATERIAL EFFECT ON THE FINANCIAL STATEMENTS. OTHER REVENUE ON FINANCIAL STATEMENTS NOT ON RETURN PART XI, LINE 2D UNREALIZED GAIN ON INTEREST RATE SWAPS 355,476 CHANGES IN ACTUARIAL ASSUMPTIONS 489,890 FAIR MARKET VALUE ADJUSTMENT ON LOANS 75,936,130 TOTAL 76,781,496 OTHER REVENUE ON RETURN NOT IN FINANCIAL STATEMENTS PART XI, LINE 4B RECLASS OF FUNDRAISING EXPENSES (232,235) RECLASS OF DEBT FINANCED RENTAL EXPENSES (194,987) TOTAL (427,222) OTHER EXPENSES INCLUDED IN FINANCIAL STATEMENT NOT ON RETURN PART XII, LINE 2D RECLASS OF FUNDRAISING EXPENSES 232,235 RECLASS OF DEBT FINANCED RENTAL EXPENSES 194,987 TOTAL 427,222 Europe (Including Iceland and Greenland) 3 Program Services GENETIC RESOURCES 221085 Central America and the Caribbean INVESTMENTS 11168563 Europe (Including Iceland and Greenland) Program Services WORKSHOP 14428 Central America and the Caribbean Program Services GENETIC RESOURCES East Asia and the Pacific Program Services GENETIC RESOURCES Europe (Including Iceland and Greenland) Program Services GENETIC RESOURCES Middle East and North Africa Program Services GENETIC RESOURCES North America Program Services GENETIC RESOURCES Russia and the Newly Independent States Program Services GENETIC RESOURCES South America Program Services GENETIC RESOURCES South Asia Program Services GENETIC RESOURCES Sub-Saharan Africa Program Services GENETIC RESOURCES 3 3 11404076 11404076 true false true true false true X X X X X X X true GRENZEBACH GLIER AND ASSOCIATES 401 NORTH MICHIGAN AVENUE SUITE 28 CHICAGO IL 60611 CONSULT false 175252 -175252 175252 -175252 CA CT FL ME MA NY PA DISCOVERY DAYS 70975 68050 2925 1379 34116 110680 82727 COOKIE'S RIDE 13080 13080 50 800 791 1692 0 84055 81130 2925 1429 34916 111471 84419 232235 -229310 true TOWN OF BAR HARBOR 93 COTTAGE STREET BAR HARBOR ME 04609 016000061 GOV'T 86000 SUPPORT MAINE MATHEMATICS AND SCIENCE ALLIANCE 219 CAPITOL STREET NO 3 AUGUSTA ME 04330 223181644 501(c)(3) 10000 SUPPORT FRIENDS OF ACADIA PO BOX 45 BAR HARBOR ME 04609 010425071 501(C)(3) 10000 SUPPORT 3 SCHOLARSHIPS/STIPENDS 387 984466 MONITOR THE USE OF GRANT FUNDS PART I, LINE 2 THE ALLOCATION OF GRANTS AND OTHER ASSISTANCE TO LOCAL ORGANIZATIONS IS DETERMINED ON AN ANNUAL BASIS. VARYING AMOUNTS OF ASSISTANCE IN THE FORM OF GRANTS, FELLOWSHIPS AND STIPENDS ARE AWARDED TO SUMMER STUDENTS, LABORATORY INTERNS, GRADUATE STUDENTS, INSTRUCTORS AND COURSE ATTENDEES BASED ON NEED AND MERIT. ALL RECIPIENTS OF GRANT FUNDS EITHER WORK AT THE LABORATORY UNDER THE SUPERVISION OF LABORATORY EMPLOYEES OR ATTEND COURSES. CONFERENCE ORGANIZERS REGULARLY MONITOR ATTENDANCE OF COURSES BY GRANT RECIPIENTS, AND RESPONSIBLE FACULTY MEMBERS OVERSEE AND MONITOR OTHER FORMS OF SCHOLARSHIP ASSISTANCE TO INDIVIDUAL STUDENTS, INTERNS OR OTHER SCIENTISTS THROUGH OVERSIGHT OF THEIR ASSIGNMENTS. X true true X X X X X false true false false false false false true false EDISON T LIU MD PRESIDENT & CEO 773896 0 150000 0 101381 0 101500 0 26298 0 1153075 0 0 0 CHARLES E HEWETT PHD EXECUTIVE VICE PRESIDENT & COO 558333 0 50000 0 1411009 0 149500 0 20455 0 2189297 0 1270544 0 LINDA A JENSEN CHIEF FINANCIAL OFFICER 315949 0 40000 0 19066 0 26500 0 18880 0 420395 0 0 0 ROBERT E BRAUN PHD VICE PRESIDENT RESEARCH 331587 0 10000 0 38467 0 26500 0 2402 0 408956 0 0 0 CHARLES LEE MD SCIENTIFIC DIRECTOR, JAX GM 295251 0 48480 0 5008 0 26500 0 29324 0 404563 0 0 0 AUROBINDO NAIR GENERAL MANAGER, JMCRS 403892 0 97500 0 22407 0 66500 0 27630 0 617929 0 0 0 KATHY L VANDEGRIFT ASSOCIATE GM FINANCE & OP 254646 0 60500 0 22349 0 26500 0 21596 0 385591 0 0 0 MIKE E HYDE VP EXTERNAL AFFAIRS & STRATE 262094 0 18000 0 59507 0 26500 0 26840 0 392941 0 0 0 JACQUES F BANCHEREAU PHD PROFESSOR 349580 0 35000 0 3562 0 26500 0 10534 0 425176 0 0 0 KRISTEN B ROZANSKY VICE PRESIDENT, DEV & COMMUN 335932 0 32640 0 770 0 24466 0 26722 0 420530 0 0 0 BRIAN R LESLIE GENERAL COUNSEL 355104 0 84375 0 2099 0 26500 0 18715 0 486793 0 0 0 BENEFITS PART I, LINE 1A TAX INDEMNIFICATION AND GROSS-UP PAYMENTS: THE JACKSON LABORATORY GROSSES UP THE AMOUNT ADDED TO WAGES FOR IMPUTED INSURANCE PREMIUMS FOR LIFE, DISABILITIY, AND LONG TERM CARE BENEFITS FOR THE SENIOR MANAGEMENT GROUP TO COVER TAXES. THE LABORATORY ALSO GROSSES UP WAGES TO COVER THE TAX IMPACT OF GIFT CARDS AND OTHER AWARDS OR PRIZES TO EMPLOYEES SO THAT THE RECIPIENTS RECEIVE THE FULL VALUE OF THE GIFT OR AWARD. EFFECTIVE IN 2015, THE LABORATORY CHANGED ITS MATCHING CONTRIBUTIONS TO PARTICIPANT ACCOUNTS IN ITS SECTION 403B RETIREMENT PLAN (THROUGH AN ANNUAL "TRUE UP" PROCESS) TO REFLECT COMPENSATION PAID TO PARTICIPANTS FOR THE FULL PLAN YEAR. SUPPLEMENTAL NONQUALIFIED RETIREMENT PLAN PART I, LINE 4B THE LABORATORY MAINTAINS A DEFERRED COMPENSATION PLAN UNDER SECTION 457(F): CONTRIBUTIONS MADE: PRESIDENT/CEO $ 75,000 EXECUTIVE VICE PRESIDENT/COO $123,000 GENERAL MANAGER, JMCRS $ 40,000 DISTRIBUTIONS FROM: EXECUTIVE VICE PRESIDENT/ COO $809,296 AND $579,609 NON-FIXED PAYMENTS PART I, LINE 7 THE TOTAL COMPENSATION PACKAGE OF CERTAIN OFFICERS, KEY EMPLOYEES, AND OTHER EMPLOYEES INCLUDES VARIABLE COMPENSATION AWARDED BASED ON PERFORMANCE. A FINANCE AUTHORITY OF MAINE 042456011 999999999 2012-08-31 42460000 REFUND false false false B ABAG FINANCE AUTHORITY FOR NONPROFIT CORPORATIONS 943130123 00037CTH3 2012-10-24 66355769 FINANCE CONSTRUCTION & REFUND false false false A 1855000 0 42460000 0 0 0 0 0 0 0 42460000 0 2002 true false true true B 1190000 0 66432099 0 0 0 623401 0 0 26665257 39143441 0 2015 false true true true A false false false true true 0.00225 0.00225 false false false false B false false true true true true 0.00303 0.00303 false false false false A false true false false true false 0 false 0 false false B false false false true false false 0 false 0 false false A true B true BOND PROCEEDS - BOND ISSUE B PART II, LINE 3 THE DIFFERENCE IN ISSUE PRICE AND LINE 3 PROCEEDS FOR BOND ISSUE B IS INTEREST INCOME FROM THE AMOUNTS HELD IN THE REFUNDING ESCROW ACCOUNT. PART IV, LINE 2(C) BOND ISSUE B - NO REBATE DUE, ARBITRAGE CALCULATION PERFORMED 01/05/2016 BY AMTEC (REFLECTING ACTIVITY THROUGH 10/31/2015). WRITTEN PROCEDURES THE JACKSON LABORATORY MONITORS THEIR TAX EXEMPT BONDS FOR POST ISSUANCE COMPLIANCE. WRITTEN PROCEDURES WERE APPROVED ON JANUARY 12, 2016. BANGOR SAVINGS BANK OFFICER - CHARLES HEWETT 1319022 CREDIT CARD PROCESSING FEES false MADELEINE BRAUN PHD KEY EMPLOYEE - R. BRAUN 245677 EMPLOYMENT - FAMILY MEMBER false X 33 3706571 FMV false true false CONTRIBUTIONS PART I, COLUMN B THE NUMBER OF CONTRIBUTIONS ARE REPORTED IN COLUMN B. ORGANIZATION'S MISSION FORM 990, PART III, LINE 1 THE MISSION OF THE LABORATORY IS TO DISCOVER PRECISE GENOMIC SOLUTIONS FOR DISEASE AND EMPOWER THE GLOBAL BIOMEDICAL COMMUNITY IN THE SHARED QUEST TO IMPROVE HUMAN HEALTH. TO ACCOMPLISH THIS MISSION, THE LABORATORY: 1) CONDUCTS BASIC BIOMEDICAL RESEARCH TO INCREASE THE KNOWLEDGE OF DEVELOPMENT, GROWTH, REPRODUCTION, PHYSIOLOGY, AND PATHOPHYSIOLOGY THROUGH RESEARCH WITH GENETICALLY DEFINED EXPERIMENTAL MOUSE MODELS AND OTHER MODELS OF DISEASE; 2) CONDUCTS TRANSLATIONAL BIOMEDICAL RESEARCH TO IDENTIFY THE GENOMIC IMPACT ON HUMAN DISEASE, PROMOTE THE ESTABLISHMENT OF MORE PRECISE, TARGETED THERAPIES, OFFER CUTTING EDGE GENOMIC DIAGNOSTICS TO IMPROVE PATIENT CARE, AND PROVIDE ADVANCED COMPUTATIONAL TOOLS, DATABASES AND KNOWLEDGE MANAGEMENT SYSTEMS TO THE BIOMEDICAL RESEARCH AND MEDICAL COMMUNITIES; 3) TRAINS AND EDUCATES STUDENTS, SCIENTISTS, PHYSICIANS, AND OTHER PROFESSIONALS IN THESE AREAS; AND 4) PROMOTES SCIENTIFIC DISCOVERY THROUGH THE PROVISION OF MOUSE MODELS AND OTHER MODELS OF HUMAN DISEASE AND THE PROVISION OF RESEARCH, CLINICAL, COMPUTATIONAL AND INFORMATION SERVICES TO THE GLOBAL SCIENTIFIC AND MEDICAL COMMUNITIES. PROGRAM SERVICES FORM 990, PART III, LINE 4A-4C DEVELOP AND PROVIDE GENETIC RESOURCES THE JACKSON LABORATORY MOUSE REPOSITORY, PRODUCTION AND RESEARCH SERVICES ARE INCLUDED AMONG THE PREMIER RESOURCES AVAILABLE TO BIOMEDICAL RESEARCHERS. IN 2015, OVER 130 COMMON LABORATORY STRAINS AS WELL AS THOUSANDS OF SELECT MUTANT AND GENETICALLY MODIFIED STRAINS OF JAX MICE WERE DISTRIBUTED TO OVER 10,000 INVESTIGATORS IN MORE THAN 1,300 INSTITUTIONS IN AT LEAST 60 COUNTRIES. DISTRIBUTION OF THESE STRAINS SUPPORTS RESEARCHERS SEEKING CURES FOR THE WORLDS MOST PREVALENT HUMAN DISEASES AND HELPS SHRINK THE TIMELINE REQUIRED TO BRING NEW THERAPIES TO PATIENTS IN NEED. THE JACKSON LABORATORY MOUSE REPOSITORY, PRODUCTION AND RESEARCH SERVICES COLLECTS DATA CONCERNING THE BREEDING, HUSBANDRY, MAINTENANCE AND DEVELOPMENT OF MOUSE MODELS THAT BECOMES PART OF THE REPOSITORY OF KNOWLEDGE AND IS SHARED WITH THE GLOBAL MOUSE RESEARCH AND BIOMEDICAL COMMUNITY TO FOSTER ETHICAL, INFORMED USE OF THESE ANIMALS IN SCIENTIFIC DISCOVERY. IN 2015 THIS DATA WAS SHARED IN OVER 150 EDUCATIONAL SEMINARS, ATTENDED BY OVER 10,000 RESEARCHERS. DATA FROM THE JACKSON LABORATORYS MOUSE DEVELOPMENT RESEARCH IS ALSO SHARED VIA PEER REVIEWED PUBLICATIONS AND PUBLICLY ACCESSIBLE DATABASES. THESE INCLUDE THE MOUSE PHENOME DATABASE (MPD) AND THE MOUSE TUMOR BIOLOGY (MTB) DATABASE. NEW IN 2015, GENOMICS, GENE EXPRESSION, AND GENE VARIANT DATA FROM OVER 100 CLINICALLY RELEVANT PATIENT DERIVED XENOGRAFT (PDX) MOUSE MODELS AND DRUG EFFICACY DATA FROM TEN OF THESE HUMAN TUMOR PDX MODELS WERE CONTRIBUTED TO THE MTB DATABASE. INFORMATION CONTRIBUTED TO MTB AS WELL AS MPD INFORMS APPROPRIATE MODEL SELECTION FOR PRECISE PRECLINICAL RESEARCH APPLICATIONS THAT CONTRIBUTES TO DRUG DEVELOPMENT PROGRAMS. TO BETTER UNDERSTAND THE ROLE OF THE HUMAN IMMUNE SYSTEM IN DISEASES SUCH AS CANCER, THE JACKSON LABORATORY DEVELOPED THE NEW HUMANIZED NSG-SGM3 MODEL. THROUGH THE JACKSON LABORATORYS EDUCATIONAL OUTREACH, THIS MODEL HAS BEGUN TO BE READILY ACCESSED IN 2015 BY RESEARCHERS AND DRUG DEVELOPMENT SCIENTISTS WHO SEEK TO UNDERSTAND HOW THE HUMAN IMMUNE SYSTEM INTERACTS WITH HUMAN TUMORS IN THE CONTEXT OF A SMALL ANIMAL MODEL. THE JACKSON LABORATORY, THE UNIVERSITY OF CALIFORNIA DAVIS AND OTHER CANCER HOSPITALS ARE CONTINUING TO PARTNER TO BUILD THE PRIMARY HUMAN TUMORS CONSORTIUM, A PUBLICLY AVAILABLE LIBRARY OF PRIMARY HUMAN TUMORS FOR RESEARCH AND DRUG DEVELOPMENT. BY JOINING THE CONSORTIUM, MEMBERS WILL CONTRIBUTE TO AND SHARE IN A TUMOR LIBRARY THAT WILL VASTLY EXCEED WHAT ANY ONE INSTITUTION COULD BUILD ON ITS OWN. THIS SHARED RESOURCE ULTIMATELY WILL GREATLY EXPAND RESEARCH CAPACITY FOR ALL CONSORTIUM PARTNERS WHILE PRESERVING VARIED AND VALUABLE TUMORS FOR FUTURE RESEARCH. THE JACKSON LABORATORY NOW HAS ESTABLISHED GREATER THAN 350 MODELS THAT ARE READILY AVAILABLE BEYOND THE CONSORTIUM PARTNERS. THE GENOMICS DATA IS ALSO PROVIDED TO ANYONE IN THE BROADER SCIENTIFIC COMMUNITY ON REQUEST. THE JACKSON LABORATORY FOR GENOMIC MEDICINE HAS PARTNERED WITH EASTERN MAINE COMMUNITY HOSPITAL TO ESTABLISH A CLINICAL OBSERVATION STUDY THAT PROSPECTIVELY TRACKS 25 CANCER PATIENTS THROUGH THEIR TREATMENT STRATEGIES. THIS JAX-FUNDED STUDY WILL RESEARCH THE UTILITY OF THE JAX CANCER TREATMENT PROFILE GENOMIC DIAGNOSTIC ASSAY AND UNDERSTAND THE IMPACT ON PATIENT OUTCOME. EDUCATION AND TRAINING IN 2015 A NEW, ONLINE JACKSON LABORATORY CONTINUING MEDICAL EDUCATION (CME) PROGRAM WAS DESIGNED AND OFFERED FOR PHYSICIANS TO BETTER PREPARE PATIENTS FOR CANCER GENETIC TESTING. FOR PATIENTS AT HIGH RISK FOR HAVING A HEREDITARY CANCER SYNDROME, GENETIC TESTING MAY BE APPROPRIATE. PRE-TEST DECISIONS & COUNSELING FOCUSES ON THE BENEFITS AND LIMITATIONS OF TESTING, AND PROVIDES THE OPPORTUNITY TO PRACTICE DECIDING WHETHER TESTING IS THE BEST CHOICE FOR A SPECIFIC PATIENT. PRE-TEST DECISIONS & COUNSELING IS THE FIRST IN A SERIES OF FREE, ONLINE CME PROGRAMS ON CANCER GENETIC TESTING THAT THE JACKSON LABORATORY WILL OFFER. SUPPORTED BY EDUCATIONAL GRANTS FROM THE MAINE CANCER FOUNDATION AND THE JACKSON LABORATORY DIRECTORS INNOVATION FUND, THE PROGRAM JOINS THE LABORATORYS GROWING ROSTER OF CONTINUING EDUCATION PROGRAMS DESIGNED TO HELP HEALTH CARE PROVIDERS INTEGRATE GENETICS AND GENOMICS INTO CLINICAL CARE. THE JACKSON LABORATORY FOR GENOMIC MEDICINE BECAME A PARTNER WITH THE CONNECTICUT STATE UNIVERSITY SYSTEM IN THE GENOMICS WORKFORCE CONSORTIUM, AN INITIATIVE TO HELP STUDENTS ACQUIRE THE KNOWLEDGE AND SKILLS NEEDED TO COMPETE FOR JOBS IN THE STATES BIOSCIENCES SECTOR. JAX ALSO HOSTED THE SECOND BIOSCIENCE CAREERS FORUM, WHERE INDUSTRY LEADERS ADVISED CONNECTICUT STUDENTS ON PREPARING FOR THEIR FUTURE PROFESSIONS. JACKSON LABORATORY OFFICIALS AND SCIENTISTS VISITED EWHA WOMANS UNIVERSITY IN SEOUL, SOUTH KOREA, FOR AN INTERNATIONAL JOINT SYMPOSIUM ON GENOMIC MEDICINE AS THE FIRST STEP IN DEVELOPING COOPERATIVE INITIATIVES IN GENOMICS-BASED MEDICAL RESEARCH. "TEACHING THE GENOME GENERATION" WAS A NEW PROGRAM INTRODUCED IN 2015. IT IS AN INNOVATIVE PROGRAM TO GIVE HIGH SCHOOL SCIENCE AND MATH TEACHERS THE TOOLS TO TEACH GENETICS AND GENOMICS THROUGH THE LENS OF PERSONALIZED MEDICINE. IN COURSES PRESENTED AT JAX CAMPUSES IN BAR HARBOR, MAINE, AND FARMINGTON, CONN., PARTICIPANTS CONDUCTED CLASSROOM EXPERIMENTS, COLLECTED AND ANALYZED REAL DATA, AND DISCUSSED THE ETHICAL COMPLEXITIES OF RESEARCH. BIOMEDICAL RESEARCH THE NATIONAL INSTITUTE ON AGING ANNOUNCED A GRANT OF $3.6 MILLION TO JAX ASSISTANT PROFESSOR GARETH HOWELL, PH.D., AND HARVARD UNIVERSITY ASSISTANT PROFESSOR BETH STEVENS, PH.D., FOR RESEARCH IN MECHANISMS OF ALZHEIMERS DISEASE. THE HOWELL LAB IS STUDYING CERTAIN CELLS THAT ARE PART OF THE IMMUNE SYSTEMS COMPLEMENT CASCADE. KNOWN AS COMPLEMENT-EXPRESSING MYELOID CELLS, THESE CELLS APPEAR TO CAUSE SOME OF THE DAMAGE TO SYNAPSES AND BLOOD VESSELS DURING AGING AND THE EARLY STAGES OF ALZHEIMERS DISEASE. THE NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM AWARDED A $2 MILLION GRANT TO JAX ASSOCIATE PROFESSOR ELISSA CHESLER, PH.D., TO DEVELOP ONLINE RESOURCES TO AID RESEARCHERS IN THE STUDY OF GENES ASSOCIATED WITH ALCOHOLISM AND ADDICTION. CHESLERS LAB FOCUSES ON COMPUTATIONAL STRATEGIES FOR THE BEHAVIORAL NEUROSCIENCES. JAX PROFESSOR ROBERT BURGESS, PH.D., RECEIVED NEARLY $1 MILLION IN FUNDING - $162,500 FROM THE NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE AND $300,000 FROM THE MUSCULAR DYSTROPHY ASSOCIATION - FOR HIS WORK IN UNDERSTANDING THE GENETIC BASIS FOR A NEUROLOGICAL DISORDER KNOWN AS CHARCOT-MARIE-TOOTH DISEASE (CMT). CMT IS A GENETIC NEUROLOGICAL DISORDER THAT CAUSES DAMAGE TO THE PERIPHERAL NERVES, THE BUNDLES OF NERVE CELL FIBERS THAT CONNECT THE BRAIN AND SPINAL CORD TO MUSCLES AND SENSORY ORGANS. A MULTI-INSTITUTIONAL GROUP OF LEADING MICROBIOME RESEARCHERS INCLUDING JAX PROFESSOR GEORGE WEINSTOCK, PH.D., ANNOUNCED THE FORMATION OF A CONSORTIUM TO "UNDERSTAND AND HARNESS THE CAPABILITIES OF THE EARTH'S MICROBIAL ECOSYSTEMS." THE UNIFIED MICROBIOME INITIATIVE (UMI) BRINGS TOGETHER U.S.-BASED SCIENTISTS DRAWN FROM MULTIPLE DISCIPLINES AND ACROSS THE ACADEMIC, NONPROFIT AND BIOTECH SPHERES TO ACCELERATE BASIC MICROBIOME RESEARCH AND ITS TRANSLATION TO USEFUL APPLICATIONS IN MEDICINE, ENGINEERING AND BEYOND. WEINSTOCK AND COLLEAGUES AT HARVARD MEDICAL SCHOOL AND OTHER INSTITUTIONS PUBLISHED A STUDY OF THE IMPACT OF INTRAVENOUSLY ADMINISTERED ANTIBIOTICS ON THE MICROBIOMES OF NEWBORN INFANTS. JAX ASSISTANT PROFESSOR JULIA OH, PH.D., WAS THE LEAD AUTHOR OF A PAPER DEMONSTRATING THE USE OF SINGLE MOLECULE SEQUENCING TO BETTER IDENTIFY AND CHARACTERIZE THE COLONIES OF MICROORGANISMS THAT LIVE ON HUMAN SKIN. AT JAXS CENTER FOR SINGLE CELL GENOMICS, PAUL ROBSON, PH.D., DIRECTOR, AND HIS COLLEAGUES ARE SEIZING THE REMARKABLE OPPORTUNITIES IN THIS NEW FIELD IN A JOINT EFFORT WITH THE UNIVERSITY OF CONNECTICUT, INCLUDING UCONN HEALTH. FOR EXAMPLE, JAX ASSISTANT PROFESSOR MICHAEL STITZEL, PH.D., IS EXPLORING KEY QUESTIONS IN TYPE 2 DIABETES BY PROBING THE ISLET CELLS THAT RESIDE IN SMALL CLUSTERS OF THE PANCREAS. JAX SCIENTISTS ALSO PROFILED TUMORS FROM CANCER PATIENTS TO DETERMINE THEIR PRECISE CELLULAR MAKEUP. FORM 990 REVIEW PROCESS FORM 990, PART VI, SECTION B, QUESTION 11B THE AUDIT COMMITTEE OF THE JACKSON LABORATORY'S BOARD OF TRUSTEES REVIEWS A DRAFT COPY OF THE IRS FORM 990 BEFORE IT IS PROVIDED TO THE BOARD OF TRUSTEES. AFTER THE AUDIT COMMITTEE'S REVIEW, THE IRS FORM 990 IS FINALIZED AND PROVIDED TO THE BOARD OF TRUSTEES PRIOR TO FILING WITH THE INTERNAL REVENUE SERVICE. CONFLICT OF INTEREST POLICY FORM 990, PART VI, SECTION B, QUESTION 12C THE JACKSON LABORATORY PROVIDES ALL OFFICERS, BOARD MEMBERS AND KEY EMPLOYEES WITH A CONFLICT OF INTEREST, CODE OF ETHICS AND DISCLOSURE FORMS AS WELL AS THE DISTRIBUTION OF ALL POLICIES REGARDING THE CONFLICT OF INTEREST AND CODE OF ETHICS. THIS PROCESS IS DONE ANNUALLY. THE DISCLOSURE AND COMPLIANCE ATTESTATIONS ARE RETURNED TO THE GENERAL COUNSEL, WHERE THEY ARE RECORDED AND TALLIED FOR COMPLETENESS. DISCLOSURES, AS WELL AS ANY FOLLOW UP QUESTIONS, ARE ROUTED THROUGH GENERAL COUNSEL, AND IF NECESSARY THE AUDIT COMMITTEE. TRUSTEES AND EXECUTIVES WITH AN APPARENT OR ACTUAL CONFLICT OF INTEREST RECUSE THEMSELVES FROM DECISION MAKING. COMPENSATION POLICY FORM 990, PART VI, SECTION B, QUESTION 15B THE COMPENSATION AND HUMAN RESOURCES COMMITTEE OF THE BOARD OF TRUSTEES SETS COMPENSATION AND BENEFITS FOR THE CHIEF EXECUTIVE OFFICER, EXECUTIVE VICE PRESIDENT AND CHIEF OPERATING OFFICER, THE VICE PRESIDENT OF RESEARCH, THE VICE PRESIDENT OF EXTERNAL AFFAIRS AND STRATEGIC PARTNERSHIPS, THE CHIEF FINANCIAL OFFICER AND EQUIVALENT POSITIONS AS WELL AS ANY OTHER EMPLOYEES OF THE LABORATORY WHO WOULD BE CONSIDERED 'INSIDERS'DISQUALIFIED PERSONS' WITHIN THE MEANING OF THE INTERMEDIATE SANCTIONS RULES UNDER THE INTERNAL REVENUE CODE. MEMBERS OF THE COMMITTEE ARE INDEPENDENT TRUSTEES SELECTED BY THE CHAIR OF THE BOARD OF TRUSTEES. THE COMMITTEE IS GUIDED BY MARKET DATA OF COMPENSATION PACKAGES FOR SIMILAR POSITIONS IN COMPARABLE ORGANIZATIONS. MARKET DATA IS PREPARED FOR THE COMMITTEE BY AN EXTERNAL EXECUTIVE COMPENSATION FIRM WHICH CONSIDERS COMPENSATION INFORMATION REPORTED IN FORM 990'S OF COMPARABLE ORGANIZATIONS AND THE RESULTS OF RECOGNIZED COMPENSATION SURVEYS. THE SENIOR DIRECTOR OF HUMAN RESOURCES IS AVAILABLE TO THE COMMITTEE TO PROVIDE ANY OTHER DATA NEEDED. THE CEO MEETS WITH THE COMMITTEE AT LEAST ANNUALLY TO PROVIDE THE COMMITTEE MEMBERS WITH ANNUAL PERFORMANCE REVIEWS OF HIS REPORTS. THE COMMITTEE'S REVIEW PROCESS AND RESULTS ARE DOCUMENTED IN MINUTES OF THE MEETINGS. PUBLIC DISCLOSURE FORM 990, PART VI, SECTION C, QUESTION 19 THE ORGANIZATION'S FORM 990 IS AVAILABLE ON WWW.GUIDESTAR.ORG AND ON THE ORGANIZATION'S PUBLIC WEBSITE WWW.JAX.ORG. THE ORGANIZATION'S FINANCIAL STATEMENTS AND CONFLICT OF INTEREST POLICY IS ALSO AVAILABLE AT WWW.JAX.ORG. THE GOVERNING DOCUMENTS ARE MADE AVAILABLE TO THE PUBLIC UPON REQUEST. OFFICERS & KEY EMPLOYEES PART VII THE LABORATORY DISCLOSES COMPENSATION INFORMATION FOR OFFICERS WITH DECISION-MAKING AND BUDGET AUTHORITY PURSUANT TO THE CORPORATIONS BYLAWS AND BOARD RESOLUTIONS. THE LABORATORY ALSO DISCLOSES KEY EMPLOYEES THAT MEET THE RESPONSIBILITY TEST AND COMPENSATION REPORTING THRESHOLD PURSUANT TO THE INSTRUCTIONS OF THE FORM 990. DURING 2015, THE LABORATORY CONDUCTED FURTHER ANALYSIS OF ITS OFFICERS AND KEY EMPLOYEES AND DETERMINED CERTAIN INDIVIDUALS DID NOT MEET THE REPORTING CRITERIA. INDIVIDUALS WHO DID NOT MEET THE REPORTING CRITERIA WERE REMOVED FROM THE FORM 990 FOR TAX YEAR 2015. THE INDIVIDUALS THAT WERE REMOVED FROM THE RETURN WERE ALSO NOT INCLUDED AS "FORMER" OFFICERS OR KEY EMPLOYEES FOR 2015 SINCE THEY WERE DETERMINED TO NOT ORIGINALLY MEET THE REQUISITE CRITERIA. THE LABORATORY STRIVES FOR TRANSPARENT REPORTING AS DEMONSTRATED BY MAKING ITS FORM 990 AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC ON ITS WEBSITE AS WELL AS FOR FULL COMPLIANCE WITH ALL TAX REPORTING REQUIREMENTS. SECURED MORTGAGES AND NOTES PAYABLE FORM 990, PART X, LINE 23 REPAYMENT TERMS: THE CT INNOVATIONS LOANS WILL BE FORGIVEN IF AND WHEN THE LABORATORY MEETS AN EMPLOYMENT GOAL OF AT LEAST 300 EMPLOYEES LOCATED IN CONNECTICUT FOR A PERIOD OF SIX MONTHS, INCLUDING A MINIMUM OF 90 SENIOR SCIENTISTS. IN ADDITION, THE AVERAGE WAGE FOR SUCH EMPLOYEES MUST EXCEED A MINIMUM TARGET LEVEL. OTHER CHANGES IN NET ASSETS FORM 990, PART XI, LINE 9 UNREALIZED GAIN ON INTEREST RATE SWAPS 355,476 CHANGES IN ACTUARIAL ASSUMPTIONS 489,890 FAIR MARKET VALUE ADJUSTMENT ON LOANS 75,936,130 TOTAL 76,781,496